YolTech Therapeutics

China was once zipping ahead of the US in clinical trials of #CRISPR therapies. The CRISPR baby scandal of 2018 stalled the country's progress. Now, a resurgence of gene editing trials are underway at Chinese biotechs, including YolTech Therapeutics, CorrectSequence Therapeutics, and HuidaGene Therapeutics Read more in my article for Endpoints News: https://lnkd.in/ed9rpUSS #geneediting #crisprtherapy #genetherapy #China #biotech #startup #clinicaltrial #drugdiscovery #drugdevelopment #Chinesebiotech

Exciting to see YolTech Therapeutics featured in @Endpoints News! As China leads the resurgence in gene editing trials, we're proud to be at the forefront of this groundbreaking research. Please follow us for more updates on our contributions and the latest developments in gene editing therapies. Read the full article below. #geneediting #crisprtherapy #genetherapy #biotech #clinicaltrial #Chinesebiotech #Yoltech

Excited to share the latest milestone from YolTech Therapeutics —— Our team's dedication to genetic innovation has resulted in the procurement of a patent for our DNA editing system. Granted by the National Intellectual Property Administration (CNIPA), this patent serves as the basis for an international Patent Cooperation Treaty (PCT) application. Click here for more information: https://lnkd.in/gyTBnpYW

YolTech Therapeutics is actively pursuing strategic collaborations at the 2024 Cell & Gene Meeting on the Mediterranean. Our team is engaged in discussions with industry leaders to explore partnership opportunities in gene editing. If you are interested in partnering with us, please reach out to discuss potential collaborations until April 11th! #YolTech #CellGeneMeeting #CGMed24

YolTech Therapeutics is actively pursuing strategic collaborations at the 2024 Cell & Gene Meeting on the Mediterranean. Our team is engaged in discussions with industry leaders to explore partnership opportunities in gene editing. If you are interested in partnering with us, please reach out to discuss potential collaborations until April 11th! #YolTech #CellGeneMeeting #CGMed24

YolTech Therapeutics has hit a major milestone! 🎉 Our gene editing therapy, YOLT-101, just nailed its first dosing. And check this out: in preclinical trials, it slashed LDL-C levels in non-human primate models for almost two years with just one dose! 😲 This breakthrough highlights our dedication to pushing boundaries in treating Familial Hypercholesterolemia and other genetic disorders. We can't wait to see YOLT-101 make waves and transform lives. Huge shoutout to our incredible team, clinical partners, and supportive collaborators - this journey wouldn't be possible without you! 🙌 #YolTech #GeneEditing #HealthcareInnovation #MedicalBreakthrough"

YolTech Therapeutics has hit a major milestone! 🎉 Our gene editing therapy, YOLT-101, just nailed its first dosing. And check this out: in preclinical trials, it slashed LDL-C levels in non-human primate models for almost two years with just one dose! 😲 This breakthrough highlights our dedication to pushing boundaries in treating Familial Hypercholesterolemia and other genetic disorders. We can't wait to see YOLT-101 make waves and transform lives. Huge shoutout to our incredible team, clinical partners, and supportive collaborators - this journey wouldn't be possible without you! 🙌 #YolTech #GeneEditing #HealthcareInnovation #MedicalBreakthrough"

🚀 YolTech Therapeutics Named Among China's Top 15 Innovative Pharma Newcomers! 🏆 Thrilled to share that we've clinched a spot on the prestigious "China's Top 15 Innovative Pharmaceutical Newcomers" list at the 2024 PMC Pharmaceutical Investment and Financing Summit in Shanghai! 🎉 Let's keep innovating for a healthier future! 💊 #YolTech #InnovationInPharma #PMC2024 #Top15Innovators 🌟

💥YolTech is gearing up for the 2024 Cell & Gene Meeting on the Mediterranean, and we're bringing the gene editing party to Rome! 🇷🇴From April 9th to 11th, catch us at this epic event as we unveil our latest innovations in gene editing and mingle with the coolest minds in the field. Click the article below to join the fun and learn more! Don't hesitate to drop us a message - we'd love to connect and chat about all things gene editing! #YolTech #CellGeneMixer #InnovateWithUs #CGMed24

We are thrilled to share a groundbreaking study recently published in 2024, exploring the dynamic synergy between CAR-T therapy and Lipid Nanoparticles. This pioneering research were conducted by Michael J Mitchell Lab Penn Bioengineering PhD student Ann Metzloff. In collaboration with University of Pennsylvania School of Veterinary Medicine and University of Pennsylvania Perelman School of Medicine. The study delves into the efficacy of aLNPs in reducing tumor burden in murine xenograft model using our very own Reagent Rabbit anti-mouse FMC63 ScFV Monoclonal Antibody. The successful use of our reagent in their research underscores the potential of our products to contribute significantly to medical advancement and epitomizes the essence of progress in the medical field, demonstrating the impactful outcomes when cutting-edge research meets quality reagents. We extend our deepest gratitude to the brilliant minds behind this paper for choosing our reagent in their vital research. Your work is paving the way for new discoveries in the battle against cancer, and we are proud to have played a part in it. We eagerly look forward to more innovations from these distinguished authors and departments. For a detailed dive into their findings, please refer to the attached PDF. Together, let's celebrate this milestone and continue to support research that makes a difference! #CARTTherapy #LipidNanoparticles #MedicalInnovation #ResearchAndDevelopment #ThankYou #Collaboration #UniversityOfPennsylvania #Bioengineering #Pathobiology #AbramsonCancerCenter